NKTR
Nektar Therapeutics · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -19.9% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +13 | 18.28M | $1.28B | +22 | −8 |
| Q1 2026 | 67 | +13 | 13.34M | $957.94M | +15 | −3 |
| Q4 2025 | 55 | +1 | 8.38M | $354.26M | +2 | — |
| Q3 2025 | 15 | 0 | 5.00M | $284.66M | +2 | −2 |
| Q2 2025 | 12 | -1 | 3.08M | $79.53M | +1 | −2 |
| Q1 2025 | 10 | -1 | 25.55M | $17.36M | — | −1 |
| Q4 2024 | 11 | 0 | 24.86M | $23.13M | — | — |
| Q3 2024 | 10 | +2 | 27.79M | $36.10M | +2 | — |
| Q2 2024 | 8 | — | 27.40M | $33.98M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 5.54M | -6.3% | $5.15M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Millennium Management ✦ | 4.52M | -10.6% | $4.21M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.96M | -0.1% | $3.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.96M | -0.1% | $3.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 3.91M | +17.5% | $3.64M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 3.27M | — | $3.04M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.54M | +12.8% | $1.43M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 833.26K | +66.1% | $774,928 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 833.26K | +66.1% | $774,928 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 833.26K | +66.1% | $774,928 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 522.41K | +10.4% | $485,840 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 522.41K | +10.4% | $485,840 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 397.04K | -94.3% | $369,248 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 192.98K | +6.0% | $180,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 175.19K | +267.0% | $162,929 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 13.40K shares, $964 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 418 sh · $30,088
Officer · 186 sh · $13,388
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology